BMC medical informatics and decision making
Aug 8, 2025
BACKGROUND: Anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) immunotherapy has revolutionized cancer treatment. However, it can cause immune-related adverse events, including acute kidney injury (AKI). Such adverse e...
Immune checkpoint inhibitors (ICIs), either as monotherapy (ICI-Mono) or combined with chemotherapy (ICI-Chemo), improves survival in advanced non-small cell lung cancer (NSCLC). However, prospective guidance for choosing between these options remain...
BACKGROUND: PD-1/PD-L1 immunotherapy represents the primary treatment for advanced NSCLC patients; however, response rates to this therapy vary among individuals. This dual-center study aimed to integrate habitat radiomics and multi-instance deep lea...
This study developed an immune-related long non-coding RNAs (lncRNAs)-based prognostic signature by integrating multi-omics data and machine learning algorithms to predict survival and therapeutic responses in breast cancer patients. Utilizing transc...
Some studies have developed machine learning (ML) models for the prediction of pneumonitis following immunotherapy and radiotherapy for patients with lung cancer (LC). However, the prediction accuracy of these models remains a topic of debate. Thus, ...
Cancer imaging : the official publication of the International Cancer Imaging Society
Jun 6, 2025
BACKGROUND: While triplet therapy (HTI), which combines hepatic arterial infusion chemotherapy (HAIC) with tyrosine kinase inhibitors and immune checkpoint inhibitors, is widely used in the treatment of large hepatocellular carcinoma (HCC), there are...
BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed the oncology treatment landscape. Despite substantial improvements for some patients, the majority do not benefit from ICIs, indicating a need for predictive biomarkers to better inform...
BACKGROUND: Immune Checkpoint Inhibitor-related Pneumonitis (CIP) exhibits high morbidity and mortality rates in the real world, often coexisting with pneumonia, particularly after immunochemotherapy. We aimed to develop and validate a non-invasive n...
International journal of surgery (London, England)
May 1, 2025
BACKGROUND: The majority of patients with hepatocellular carcinoma (HCC) miss the opportunity of radical resection, making immune check-point inhibitors (ICIs)-based conversion therapy a primary option. However, challenges persist in predicting respo...
PURPOSE: Anti-PD-1 antibodies are widely used for cancer treatment, including in advanced renal cell carcinoma (RCC). However, the therapeutic response varies among patients. This study aimed to predict tumor response to nivolumab anti-PD-1 antibody ...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.